Welcome to our dedicated page for PMGC Holdings SEC filings (Ticker: ELAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PMGC Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PMGC Holdings's regulatory disclosures and financial reporting.
PMGC Holdings Inc., through its wholly owned subsidiaries, entered into a Merger Agreement to combine AGA Precision Systems LLC with A&B Aerospace, Inc. AGA will merge into A&B, with A&B as the surviving entity.
All membership interests in AGA will be cancelled without consideration, while all issued and outstanding shares of A&B will remain outstanding and unchanged. The merger will be completed upon filing a Certificate of Merger with the California Secretary of State, with an anticipated effective date of July 2, 2026.
PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Defense Tech LLC, entered into a Standard Exclusive License Agreement effective June 30, 2026. The deal grants a worldwide, non-transferable, exclusive license to make, use, and sell products covered by U.S. Patent No. 12,291,334 and related know-how in aerospace and defense technologies, with rights to grant sublicenses.
NorthStrive Defense Tech must follow a development plan, provide detailed annual progress reports, and meet diligence milestones, with failure potentially constituting a material breach unless extensions are granted. Consideration includes a non-refundable license issue fee, annual maintenance fees until first Net Sales, ongoing royalties, and sublicense payments over a product- and country-specific Royalty Term that lasts until patent expiry or twelve years from first Net Sale, whichever is later.
The License Agreement includes termination rights for both parties, including nonpayment, uncured breaches, repeated payment defaults, and insolvency events. Key definitions cover Know-How, Licensed Products, Patent Rights, and Royalty Term, and the full agreement is filed as Exhibit 10.1.
PMGC Holdings Inc., through subsidiary NorthStrive Biosciences, reported positive Phase III results from its AI-driven drug discovery program with Yuva Biosciences.
Four AI-selected small molecules (C1–C4) significantly increased ANT1 protein expression in primary human skeletal muscle cells, with dose-dependent gains up to 50%. The partners plan confirmatory testing in a more mature skeletal muscle model to validate ANT1 induction as part of PMGC’s broader muscle-preservation strategy, including potential use alongside GLP-1 weight-loss treatments. The company emphasizes these in vitro findings are preliminary and subject to substantial development, regulatory and commercial risks.
PMGC Holdings Inc., which trades on Nasdaq under the symbol ELAB, reported results from its 2026 Annual Meeting and a key change to its corporate governance. Shareholders approved amended bylaws that classify the Board of Directors into two staggered classes, Class I and Class II, with different term lengths.
The staggered structure will start after the 2027 Annual Meeting. Initial Class I directors will serve until the 2030 Annual Meeting, and initial Class II directors will serve until the 2028 meeting. At the 2026 Annual Meeting, all five director nominees were elected with about 99.8% of votes cast, and shareholders also approved the staggered board proposal and ratified HTL International, LLC as auditor for the 2026 fiscal year. A quorum was present, with 6,564,834 shares represented, or 60.13% of 10,916,625 outstanding shares entitled to vote.
PMGC Holdings Inc., through its subsidiary NorthStrive Defense Tech LLC, entered into a binding term sheet with the Florida State University Research Foundation to obtain an exclusive, worldwide, sublicensable license to patent rights related to U.S. Patent No. 12,291,334 for aerospace and defense technologies. The license includes tiered earned royalties on net sales by product category and cumulative net sales, an annual minimum royalty, a sublicensing revenue share, and an annual maintenance fee, while PMGC follows a multi-year development plan that can be adjusted by mutual agreement.
NorthStrive Defense Tech also signed an Educational Research Agreement with the Florida State University Research Foundation under which it will fund $490,657 of research by the Center for Intelligent Systems, Control, and Robotics over a 12‑month term starting June 1, 2026. Any inventions made during the research will belong to the foundation, with NorthStrive Defense Tech receiving an option to negotiate a royalty-bearing license and a royalty‑free, non‑exclusive internal use license, and either party may terminate the research agreement with 30 days’ written notice.
PMGC Holdings Inc. reported that options to acquire 450,277 shares of its common stock were granted to GB Capital Ltd., an entity wholly owned by Chief Executive Officer Graydon Bensler. The non-statutory stock options have an exercise price of $1.77 per share, are 100% vested, and immediately exercisable as of June 1, 2026.
The grant was issued as partial consideration for consultant services provided to the company through GB Capital Ltd. Following this award, GB Capital Ltd. indirectly holds options covering a total of 450,279 shares of PMGC Holdings Inc. common stock.
Braeden Lichti and Northstrive Companies Inc. amend their ownership disclosure for PMGC Holdings Inc. They report beneficial ownership of 450,313 shares of Common Stock, representing 7.40% of the class, based on 5,631,282 shares outstanding on June 1, 2026.
The stake includes 32 shares of Common Stock held by Northstrive, 2 shares underlying options previously granted to Mr. Lichti and held by Northstrive, 2 shares underlying warrants held by BWL Investments Ltd., and 450,277 shares underlying options granted to Northstrive on June 1, 2026 as partial consideration for consulting services under the issuer’s 2025 Equity Incentive Plan.
The amendment also reflects that prior holdings were reassigned from other entities to Northstrive and adjusted for multiple reverse stock splits. Both reporting persons disclose zero sole voting or dispositive power and shared power over the reported shares.
PMGC Holdings Inc. received a Schedule 13D from Graydon Bensler and his wholly owned entity GB Capital Ltd. reporting beneficial ownership of 450,287 shares of Common Stock, representing 7.40% of the class. This total includes shares underlying options granted to GB Capital Ltd. on June 1, 2026 as partial consideration for consulting services under the company’s 2025 Equity Incentive Plan. The percentage is based on 5,631,282 shares of Common Stock issued and outstanding as of June 1, 2026. Voting and dispositive power over these shares is shared between Mr. Bensler and GB Capital Ltd.
PMGC Holdings Inc. director Jeffrey Parry received a grant of stock options as part of his compensation. On June 1, 2026, he was awarded options to acquire 75,046 shares of common stock at an exercise price of $1.77 per share.
The options were granted under the company’s 2025 Equity Incentive Plan, as amended. They are non-statutory stock options that are 100% vested and immediately exercisable as of the grant date and expire on June 1, 2031. Following this grant, Parry holds 75,046 options directly.
PMGC Holdings Inc. reported that independent director Georgiy Kovalyov received a grant of stock options as compensation for his board service. The award covers 75,046 options for common stock at an exercise price of $1.77 per share, expiring on June 1, 2031.
The options were granted under the company’s 2025 Equity Incentive Plan. They are described as non-statutory stock options that are 100% vested and immediately exercisable as of the grant date, giving Kovalyov the right to acquire an equal number of common shares.